Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia.

Stamatovic L, Vasovic S, Trifunovic J, Boskov N, Gajic Z, Parezanovic A, Icevic M, Cirkovic A, Milic N.

Psychooncology. 2017 Aug 31. doi: 10.1002/pon.4551. [Epub ahead of print]

PMID:
28857314
2.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.

Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

PMID:
28625777
3.

Delays in diagnosis and treatment of breast cancer: a multinational analysis.

Jassem J, Ozmen V, Bacanu F, Drobniene M, Eglitis J, Lakshmaiah KC, Kahan Z, Mardiak J, Pieńkowski T, Semiglazova T, Stamatovic L, Timcheva C, Vasovic S, Vrbanec D, Zaborek P.

Eur J Public Health. 2014 Oct;24(5):761-7. doi: 10.1093/eurpub/ckt131. Epub 2013 Sep 12.

PMID:
24029456
4.

Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review.

Kim K, Hernlund E, Hernadi Z, Révész J, Pete I, Szánthó A, Bodnar L, Madry R, Timorek-Lemieszczuk A, Bozanovic T, Vasovic S, Tomasevic Z, Zivaljevic M, Pazin V, Minárik T, Garanová H, Helpianska L, Justo N.

Int J Gynecol Cancer. 2013 Jun;23(5):823-32. doi: 10.1097/IGC.0b013e318291e8ca.

PMID:
23666016
5.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group.

Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

PMID:
23312888
6.

Primarily tamoxifen-unresponsive, steroid receptor-positive breast cancer may respond to an aromatase inhibition: a pilot study.

Nesković-Konstantinović Z, Susnjar S, Nikolić-Vukosavljević D, Jovanović D, Vasović S, Stamatović L, Gavrilović D.

J BUON. 2005 Jan-Mar;10(1):53-8.

PMID:
17335132
7.

[Association of estrogen and progesterone receptor levels and the expected response to chemotherapy and hormone therapy in breast carcinoma with increased expression of human epidermal growth factor 2].

Susnjar S, Nesković-Konstantinović Z, Stamatović L, Vasović S, Strabic M, Nikolić-Vukosavljević D, Jovanović D.

Srp Arh Celok Lek. 2003 Nov-Dec;131(11-12):443-8. Serbian.

8.

Mitoxantrone, 5-fluorouracil and low-dose leucovorin in doxorubicin-resistant advanced breast cancer patients: a phase II study.

Susnjar S, Vasović S, Nesković-Konstantinović Z, Stamatović L, Lukić V, Colaković S, Mitrovic L, Jelić S, Radulović S.

Tumori. 1999 Nov-Dec;85(6):478-82.

PMID:
10774569
9.

[Aminoglutethimide in the treatment of metastatic breast carcinoma].

Vasović S, Nesković-Konstantinović Z, Susnjar S, Stamatović Lj, Nesković B, Mitrović L, Jelić S.

Srp Arh Celok Lek. 1999 Sep-Oct;127(9-10):333-7. Serbian. No abstract available.

PMID:
10649904
10.

[Adjuvant chemotherapy in operable breast carcinoma].

Stamatović Lj, Nesković-Konstantinović Z, Susnjar S, Vasović S, Jelić S, Mitrović L.

Srp Arh Celok Lek. 1999 Jul-Aug;127(7-8):270-5. Review. Serbian. No abstract available.

PMID:
10624403
11.

Tumour-induced hypercalcaemia, resistant to systemic anti-hypercalcaemic and chemo-endocrine treatments, but responding to radiotherapy in a breast cancer patient.

Nesković-Konstantinović Z, Susnjar S, Vasović S, Borojević N, Mitrović L, Radosević-Jelić L, Radulović S.

Acta Oncol. 1996;35(4):501-3. No abstract available.

PMID:
8695173

Supplemental Content

Loading ...
Support Center